BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
This phase 2b study is designed as multicentre, multinational, randomized, double blind,
parallel group and placebo controlled with three doses of Bavisant (0.5, 1, and 3 mg/d) in
subjects with excessive daytime sleepiness with Parkinson's disease.